Article Corrected {#Sec1}
=================

Tasocitinib. Drugs R D 2010; 10 (4): 271--284

Corrections Made {#Sec2}
================

The drug name has changed and should be referred to as 'tofacitinib' throughout the document.

**Page 271:** In the abstract, the first sentence, which previously read:

"Tasocitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant..."

has now been corrected as follows:

"[Tofacitinib]{.ul} (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant..."

**Page 271:** In the abstract, the second sentence, which previously read:

"Tasocitinib specifically inhibits Janus activated kinase 3 (JAK3), which has..."

has now been corrected as follows:

"[Tofacitinib]{.ul} inhibits Janus activated kinase 3 (JAK3), which has..."

**Page 272:** In the second paragraph of section 1.1.4, the third sentence, which previously read:

"The trial enrolled 249 *de novo* renal allograft recipients..."

has now been corrected as follows:

"The trial enrolled [61]{.ul}*de novo* renal allograft recipients..."

**Page 272:** In the second paragraph of section 1.1.4, the fifth sentence, which previously read:

"Enrollment of 54 patients was completed..."

has now been corrected as follows:

"Enrollment of [45]{.ul} patients was completed..."

**Page 272:** In the third paragraph of section 1.1.5, the first sentence, which previously read:

"...compare the efficacy of tasocitinib with methotrexate..."

has now been corrected as follows:

"...compare the efficacy [of two doses of tofacitinib]{.ul} with methotrexate..."

**Page 273:** In the left column, third paragraph, the first sentence, which previously read:

"...efficacy and safety of tasocitinib in 2500 patients...

has now been corrected as follows:

"...efficacy and safety of [tofacitinib]{.ul} in [4000]{.ul} patients..."

**Page 274:** In the first paragraph of section 2.2.2, the first sentence, which previously read:

"...were low in the phase II/III ORAL Solo trial..."

has now been corrected as follows:

"...were low in the phase [III]{.ul} ORAL Solo trial..."

**Page 275:** In the left column, second paragraph, the first sentence, which previously read:

"No new safety signals have emerged in the ongoing ORAL Sequel phase II/III 2-year extension study..."

has now been corrected as follows:

"No new safety signals have emerged [over 2 years]{.ul} in the ongoing ORAL Sequel phase II/III extension study..."

**Page 275:** In the right column, second paragraph, the first sentence, which previously read:

"In a 1-year extension study that included patients..."

has now been corrected as follows:

"[After 1 year of an extension study]{.ul} that included patients..."

**Page 275:** In the right column, third paragraph, the first sentence, which previously read:

"...at dosages of 2--20 mg/day,..."

has now been corrected as follows:

"...at [doses of 1--10 mg twice daily]{.ul},..."

**Page 277**: In the fifth paragraph of section 2.4.1, the first sentence, which previously read:

"Cynomolgus monkeys receiving tasocitinib had a significantly longer..."

has now been corrected as follows:

"Cynomolgus monkeys receiving [tofacitinib following bilateral nephrectomy and allogeneic renal transplant]{.ul} had a significantly longer..."

**Page 278:** In the right column, lines 1 and 2, which previously read:

"...twice daily groups at 6 months, compared with the placebo group."

has now been corrected as follows:

"...twice daily groups at [3]{.ul} months, compared with the placebo group."

**Page 281:** In the left column, second paragraph, which previously read:

"...significantly improved pain and physical function at 6 weeks..."

has now been corrected as follows:

"...significantly improved [ACR response rates]{.ul} at 6 weeks..."

**Page 281:** In the right column, the second paragraph starting with "One-year efficacy data..." should be deleted entirely.

**Page 281:** In the right column, third paragraph, the first sentence, which previously read:

"Tasocitinib, at dosages of 2--20 mg/day, was effective..."

has now been corrected as follows:

"[Tofacitinib, at doses of 1--10 mg twice daily]{.ul}, was effective..."

Note {#Sec3}
====

All online versions of this article have been updated to reflect these corrections.

An Erratum for this chapter can be found at <http://dx.doi.org/10.1007/BF03259722>
